You are here

EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's Disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AG076098-01
Agency Tracking Number: R41AG076098
Amount: $361,764.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIA
Solicitation Number: PA20-272
Solicitation Year: 2020
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-09-30
Award End Date (Contract End Date): 2023-09-29
Small Business Information
Rodeo, CA 94572-1808
United States
DUNS: 081096834
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (814) 777-8586
Business Contact
Phone: (814) 777-8586
Research Institution
BOSTON, MA 02115-6110
United States

 Domestic Nonprofit Research Organization

Alzheimerandapos;s disease (AD) is the most widespread neurodegenerative disorder and has caused a major global
health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental
decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating
studies indicate that neuron-derived extracellular vesicles (EVs) are important biomarkers for AD. However,
researchers face significant challenges in the efficient isolation and accurate analysis of EVs, limiting the broad
study and application of EVs in early diagnosis or targeted therapy of AD. WellSIM proposes to develop and
validate a high-throughput platform and workflow based on our revolutionary EXODUS technique for reliable and
reproducible isolation and analysis of EVs from plasma and CSF with unparalleled throughput, purity, yield, and
sensitivity. Based on hi-EXODUS-NGS and hi-EXODUS-MS integrative analysis, transcriptomic and proteomic
profiling of EVs will be developed to discover and detect EV-derived multi-class biomarkers for AD diagnosis.PROJECT NARRATIVE
One of the significant challenges for clinical validation and application of circulating EVs in AD diagnosis is the
difficulties in efficiently isolating EVs from complicated biofluids with sufficient yield and purity for accurate
interpretation. Our technique could address the unmet needs for EV isolation in AD studies, which will facilitate
early diagnosis and targeted therapy of AD as well as accelerate our understanding of AD pathogenesis and
propagation. Moreover, our study will develop and validate a new methodology and workflow for purification,
profiling, and integrative analysis of EV-derived biomolecules, providing substantial benefits to the EV research

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government